Literature DB >> 23231397

Focusing on new monoamine oxidase inhibitors: differently substituted coumarins as an interesting scaffold.

Maria João Matos1, Dolores Viña, Saleta Vazquez-Rodriguez, Eugenio Uriarte, Lourdes Santana.   

Abstract

It is commonly accepted that monoamine oxidase (MAO) may play a critical role in the regulation of the central nervous system activity and contribute to the pathogenesis of human neurodegenerative and depressive disorders. This has encouraged an active research in the development of new drugs, MAO inhibitors, since they may represent an important advance in the treatment of complex diseases such as Alzheimer and Parkinson, which are becoming prevalent pathologies due to the increase of aging population of developed countries societies. Different research groups are intensively working in this area with the aim of finding new MAO selective inhibitors. Differently substituted coumarins have been synthesized and evaluated as MAO-A and MAO-B inhibitors. The purpose of this review is to summarize the findings reported in this area, particularly focuses on the coumarin scaffold.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23231397     DOI: 10.2174/156802612805220002

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  12 in total

Review 1.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

2.  Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors.

Authors:  Bijo Mathew; Seung Cheol Baek; Della Grace Thomas Parambi; Jae Pil Lee; Monu Joy; P R Annie Rilda; Rugma V Randev; P Nithyamol; Vijitha Vijayan; Sini T Inasu; Githa Elizabeth Mathew; Krishnakumar K Lohidakshan; Girish Kumar Krishnan; Hoon Kim
Journal:  Medchemcomm       Date:  2018-09-25       Impact factor: 3.597

3.  Antioxidant Activities of 4-Methylumbelliferone Derivatives.

Authors:  Yasameen K Al-Majedy; Ahmed A Al-Amiery; Abdul Amir H Kadhum; Abu Bakar Mohamad
Journal:  PLoS One       Date:  2016-05-31       Impact factor: 3.240

4.  The Benzopyrone Biochanin-A as a reversible, competitive, and selective monoamine oxidase B inhibitor.

Authors:  Najla O Zarmouh; Suresh K Eyunni; Karam F A Soliman
Journal:  BMC Complement Altern Med       Date:  2017-01-10       Impact factor: 3.659

5.  Study of coumarin-resveratrol hybrids as potent antioxidant compounds.

Authors:  Maria J Matos; Francisco Mura; Saleta Vazquez-Rodriguez; Fernanda Borges; Lourdes Santana; Eugenio Uriarte; Claudio Olea-Azar
Journal:  Molecules       Date:  2015-02-16       Impact factor: 4.411

6.  Development of Halogenated Pyrazolines as Selective Monoamine Oxidase-B Inhibitors: Deciphering via Molecular Dynamics Approach.

Authors:  Aathira Sujathan Nair; Jong-Min Oh; Vishal Payyalot Koyiparambath; Sunil Kumar; Sachithra Thazhathuveedu Sudevan; Opeyemi Soremekun; Mahmoud E Soliman; Ahmed Khames; Mohamed A Abdelgawad; Leena K Pappachen; Bijo Mathew; Hoon Kim
Journal:  Molecules       Date:  2021-05-28       Impact factor: 4.411

7.  Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease.

Authors:  Angel Agis-Torres; Monica Sölhuber; Maria Fernandez; J M Sanchez-Montero
Journal:  Curr Neuropharmacol       Date:  2014-01       Impact factor: 7.363

8.  Structure-Activity Relationship Analysis of 3-Phenylcoumarin-Based Monoamine Oxidase B Inhibitors.

Authors:  Sanna Rauhamäki; Pekka A Postila; Sanna Niinivehmas; Sami Kortet; Emmi Schildt; Mira Pasanen; Elangovan Manivannan; Mira Ahinko; Pasi Koskimies; Niina Nyberg; Pasi Huuskonen; Elina Multamäki; Markku Pasanen; Risto O Juvonen; Hannu Raunio; Juhani Huuskonen; Olli T Pentikäinen
Journal:  Front Chem       Date:  2018-03-02       Impact factor: 5.221

9.  Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent

Authors:  María Del Pilar Olaya; Nadezdha Esperanza Vergel; José Luis López; María Dolores Viña; Mario Francisco Guerrero
Journal:  Biomedica       Date:  2019-09-01       Impact factor: 0.935

10.  Design, Synthesis, and Biological Evaluation of Pyridazinones Containing the (2-Fluorophenyl) Piperazine Moiety as Selective MAO-B Inhibitors.

Authors:  Muhammed Çeçen; Jong Min Oh; Zeynep Özdemir; Saliha Ebru Büyüktuncel; Mehtap Uysal; Mohamed A Abdelgawad; Arafa Musa; Nicola Gambacorta; Orazio Nicolotti; Bijo Mathew; Hoon Kim
Journal:  Molecules       Date:  2020-11-17       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.